3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
80
Stomach Neoplasms
64
Rectal Neoplasms
39
Pancreatic Neoplasms
31
Colonic Neoplasms
27
Esophageal Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
20
Adenocarcinoma
19
Neoplasms
18
Cholangiocarcinoma
16
Neoplasm Metastasis
15
Adenocarcinoma Of Esophagus
14
Biliary Tract Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Ovarian Neoplasms
10
Gastrointestinal Neoplasms
7
Gallbladder Neoplasms
7
Carcinoma, Hepatocellular
7
Esophageal Squamous Cell Carcinoma
6
Endometrial Neoplasms
6
Locally Advanced Rectal Cancer
5
Recurrence
4
Lymphoma
4
Carcinoma
4
Bile Duct Neoplasms
4
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Peritoneal Neoplasms
3
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Oxaliplatin
×
1 year
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts